Cargando…

Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer

Triple-negative breast cancer (TNBC) is proposed to be an immunohistochemical surrogate of the basal-like breast cancer subtype. In spite of the relative chemosensitivity of this cancer subtype, it is characterized by aggressive clinical behavior; therefore, a further subclassification of TNBC is re...

Descripción completa

Detalles Bibliográficos
Autores principales:	MAKSIMENKO, JELENA, IRMEJS, ARVIDS, NAKAZAWA-MIKLASEVICA, MIKI, MELBARDE-GORKUSA, INGA, TROFIMOVICS, GENADIJS, GARDOVSKIS, JANIS, MIKLASEVICS, EDVINS
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2014
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3861604/ https://www.ncbi.nlm.nih.gov/pubmed/24348864 http://dx.doi.org/10.3892/ol.2013.1684

Ejemplares similares

BRCA1 mutation in the Triple- Negative Breast Cancer Group
por: Maksimenko, Jelena, et al.
Publicado: (2012)

Challenges in the management of a patient with Cowden syndrome: case report and literature review
por: Melbārde-Gorkuša, Inga, et al.
Publicado: (2012)

Effectiveness of Secondary Risk–Reducing Strategies in Patients With Unilateral Breast Cancer With Pathogenic Variants of BRCA1 and BRCA2 Subjected to Breast-Conserving Surgery: Evidence-Based Simulation Study
por: Maksimenko, Jelena, et al.
Publicado: (2022)

Correction: Effectiveness of Secondary Risk–Reducing Strategies in Patients With Unilateral Breast Cancer With Pathogenic Variants of BRCA1 and BRCA2 Subjected to Breast-Conserving Surgery: Evidence-Based Simulation Study
por: Maksimenko, Jelena, et al.
Publicado: (2023)

High expression of miR-214 is associated with a worse disease-specific survival of the triple-negative breast cancer patients
por: Kalniete, Dagnija, et al.
Publicado: (2015)

Ultrasound guided needle biopsy of axilla to evaluate nodal metastasis after preoperative systemic therapy in cohort of 106 breast cancers enriched with BRCA1/2 pathogenic variant carriers
por: Līcīte, Baiba, et al.
Publicado: (2021)

BRCA1/2 mutation screening in high-risk breast/ovarian cancer families and sporadic cancer patient surveilling for hidden high-risk families
por: Berzina, Dace, et al.
Publicado: (2013)

Pilot Study on Low Penetrance Breast and Colorectal Cancer Predisposition Markers in Latvia
por: Irmejs, Arvids, et al.
Publicado: (2006)

Genotype-phenotype correlations among BRCA1 4153delA and 5382insC mutation carriers from Latvia
por: Plakhins, Grigorijs, et al.
Publicado: (2011)

Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer: a retrospective cohort analysis and literature review
por: Sæther, Nikolai Havn, et al.
Publicado: (2018)

Clinical, Molecular and Geographical Features of Hereditary Breast/Ovarian Cancer in Latvia
por: Gardovskis, Andris, et al.
Publicado: (2005)

Pregnancy after breast cancer in BRCA1/2 mutation carriers
por: Maksimenko, Jelena, et al.
Publicado: (2022)

Body mass index and nipple preservation are major contributors to satisfaction and aesthetic outcome rates after implant-based immediate breast reconstruction
por: Ukleikins, Stanislavs, et al.
Publicado: (2019)

Allelic variants of breast cancer susceptibility genes PALB2 and RECQL in the Latvian population
por: Hilz, Philip, et al.
Publicado: (2019)

Comment on the article Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology by Lubinski et al., Breast Cancer Res Treat 2008 Apr 15
por: Irmejs, Arvids, et al.
Publicado: (2008)

High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population
por: Maksimenko, J., et al.
Publicado: (2018)

Population screening for hereditary and familial cancer syndromes in Valka district of Latvia
por: Vanags, Andrejs, et al.
Publicado: (2010)

Bladder cancer trends in Latvia during 1990–2017: incidence, mortality, and survival rates
por: Bitiņa-Barlote, Ērika, et al.
Publicado: (2021)

Platinum-Based Chemotherapy Secures Effective Local Control for Very Advanced Hereditary Triple-Negative Breast Cancer with Life-Threatening Bleeding
por: Irmejs, Arvids, et al.
Publicado: (2017)

A novel frequent BRCA1 recurrent variant c.5117G > A (p.Gly1206Glu) identified after 20 years of BRCA1/2 research in the Baltic region: cohort study and literature review
por: Loza, P., et al.
Publicado: (2021)

An Effect of Culture Media on Epithelial Differentiation Markers in Breast Cancer Cell Lines MCF7, MDA-MB-436 and SkBr3
por: Pirsko, Valdis, et al.
Publicado: (2018)

The CHEK2 del5395 is a founder mutation without direct effects for cancer risk in the latvian population
por: Plonis, J, et al.
Publicado: (2016)

Chromothripsis and progression-free survival in metastatic colorectal cancer
por: Skuja, Elina, et al.
Publicado: (2017)

Polygenic Risk Score Predicts Modified Risk in BRCA1 Pathogenic Variant c.4035del and c.5266dup Carriers in Breast Cancer Patients
por: Berga-Švītiņa, Egija, et al.
Publicado: (2023)

Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer – single hospital experience
por: Sivina, Elina, et al.
Publicado: (2023)

Hereditary Colorectal Cancer (CRC) Program in Latvia
por: Irmejs, Arvids, et al.
Publicado: (2003)

Can We Predict Differentiated Thyroid Cancer Behavior? Role of Genetic and Molecular Markers
por: Niciporuka, Rita, et al.
Publicado: (2021)

Pathogenic APC Variants in Latvian Familial Adenomatous Polyposis Patients
por: Daneberga, Zanda, et al.
Publicado: (2019)

Meeting abstracts from the Annual Conference on Hereditary Cancers 2015: Szczecin, Poland. 24-25 September, 2015
por: Thompson, Ella R., et al.
Publicado: (2017)

BRCA2 Mutations and Triple-Negative Breast Cancer
por: Meyer, Peter, et al.
Publicado: (2012)

Cumulative Small Effect Genetic Markers and the Risk of Colorectal Cancer in Poland, Estonia, Lithuania, and Latvia
por: Serrano-Fernandez, Pablo, et al.
Publicado: (2015)

Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis
por: Pogoda, Katarzyna, et al.
Publicado: (2020)

Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers
por: Glodzik, Dominik, et al.
Publicado: (2020)

The Fetal Phenotype of Noonan Syndrome Caused by Severe, Cancer-Related PTPN11 Variants
por: Malniece, Ieva, et al.
Publicado: (2020)

The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancer
por: Sharma, Priyanka, et al.
Publicado: (2014)

Combining Carbon-Ion Irradiation and PARP Inhibitor, Olaparib Efficiently Kills BRCA1-Mutated Triple-Negative Breast Cancer Cells
por: Kawanishi, Miki, et al.
Publicado: (2022)

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
por: Bouwman, Peter, et al.
Publicado: (2010)

Influence of BRCA1 Germline Mutations in the Somatic Mutational Burden of Triple-Negative Breast Cancer
por: Ferreira, Elisa Napolitano, et al.
Publicado: (2019)

The prevalence of BRCA1 mutations among young women with triple-negative breast cancer
por: Young, SR, et al.
Publicado: (2009)

Triple-negative breast cancer frequency and type of BRCA mutation: Clues from Sardinia
por: PALOMBA, GRAZIA, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_7qnpch1jed3ctgvacdvqlorls9